PolanskyM.EisenstadtR.DeGraziaT.ZhaoX.LiuY.FeldmanR. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179-186.doi:10.1016/j.jaad.2019.03.049
2.
FudgeJG.CrawfordRI. Bullous pemphigoid: a 10-year study of discordant results on direct immunofluorescence. J Cutan Med Surg. 2018;22(5):472-475.doi:10.1177/1203475418773359
3.
MiyamotoD.SantiCG.AokiV.MarutaCW.pemphigoidB. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133-146.doi:10.1590/abd1806-4841.20199007
4.
LeeSG.LeeHJ.YoonMS.KimDH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155(2):172-177.doi:10.1001/jamadermatol.2018.4556
5.
LambertsA.MeijerJM.PasHH.DiercksGFH.HorváthB.JonkmanMF. Nonbullous pemphigoid: insights in clinical and diagnostic findings, treatment responses, and prognosis. J Am Acad Dermatol. 2019;81(2):355-363.doi:10.1016/j.jaad.2019.04.029
6.
KirtschigG.MiddletonP.BennettC.MurrellDF.WojnarowskaF.KhumaloNP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;10:CD002292.
7.
MikulskaM.LaniniS.GudiolCet al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24(Suppl 2):S71-S82.doi:10.1016/j.cmi.2018.02.003
8.
KremerN.SnastI.CohenESet al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209-216.doi:10.1007/s40257-018-0401-6
9.
IzumiK.BieberK.LudwigRJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978.doi:10.3389/fimmu.2019.00978
